High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23
@article{Dahlerup2016HighdoseFI, title={High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23}, author={J. Dahlerup and B. Jacobsen and J. C. van der Woude and Lars-{\AA}ke Bark and L. Thomsen and S. Lindgren}, journal={Scandinavian Journal of Gastroenterology}, year={2016}, volume={51}, pages={1332 - 1338} }
Abstract Objective: Iron isomaltoside (Monofer®) is a high-dose intravenous iron preparation with good tolerability and efficacy in inflammatory bowel disease (IBD) patients with iron deficiency anaemia (IDA). This trial evaluates the safety and efficacy, including effect on intact fibroblast growth factor 23 (iFGF23) of a high single dose and cumulative doses of iron isomaltoside in IBD patients with IDA. Materials and methods: The trial was a prospective, open-label, multi-centre trial… CONTINUE READING
Topics from this paper
25 Citations
Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice
- Medicine
- Scandinavian journal of gastroenterology
- 2018
- 5
Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
- Medicine
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
- 2020
- 15
A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia
- Medicine
- American journal of hematology
- 2017
- 39
Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders
- Medicine
- 2020
- 1
- PDF
A prospective, multi‐center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON‐IDA trial
- Medicine
- American journal of hematology
- 2019
- 15
The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency
- Medicine
- Gastroenterology research and practice
- 2017
- 13
- PDF
An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
- Medicine
- Advances in Therapy
- 2018
- 6
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
- Medicine
- JAMA
- 2020
- 29
Associations Between Intravenous Iron, Inflammation and FGF23 in Non-Dialysis Patients with Chronic Kidney Disease Stages 3-5
- Medicine
- Kidney and Blood Pressure Research
- 2018
- 8
A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy
- Medicine
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
- 2018
- 19
- PDF
References
SHOWING 1-10 OF 30 REFERENCES
A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease
- Medicine
- Scandinavian journal of gastroenterology
- 2015
- 27
A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
- Medicine
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
- 2016
- 49
- PDF
Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
- Medicine
- Journal of nephrology
- 2011
- 47
Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study
- Medicine
- 2010
- 30
A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients
- Medicine
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
- 2015
- 43
- PDF
Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement
- Medicine
- Inflammatory bowel diseases
- 2009
- 113
When is high-dose intravenous iron repletion needed? Assessing new treatment options
- Medicine
- Drug design, development and therapy
- 2011
- 58
- PDF
A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)
- Medicine
- The American Journal of Gastroenterology
- 2013
- 103
- PDF
Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations
- Medicine
- Anemia
- 2015
- 44
- PDF
Severe hypophosphataemia after intravenous iron administration.
- Medicine
- The Netherlands journal of medicine
- 2014
- 55